GRAND RAPIDS, Mich., Jan. 12 /PRNewswire-FirstCall/ -- BestNet
Communications Corp. (OTC Bulletin Board: BESC - News) announced today that
it has filed a Current Report on Form 8-K with the Securities and Exchange
Commission reporting the sale of most of the assets of its telephone
business to Interactive Media Technologies, Inc., a privately held company
located in Boca Raton, Florida. The sale for cash did not include BestNet's
rights under its license from Softalk, Inc. The actual transfer of the
assets is expected to occur within forty-five days.
According to Mr. Stanley L. Schloz, BestNet's Chief Executive Officer,
"The transaction supports our strategy to focus on our medical subsidiary,
Oncologix, and has stopped the phone business drain on cash. We are also
pleased that our telephone customers will now have the opportunity of
continuing to receive telephone services with Interactive Media
Technologies, a highly respected participant in the telecommunications
industry."
Mr. Schloz went on to say that Oncologix has completed the formation of
a Scientific Advisory Board (SAB). The SAB, along with its Chief Medical
and Science Officer Andrew S. Kennedy, MD, will provide advisement on the
development and testing of the company's Oncosphere System.
The SAB membership represents key areas of expertise involved in
microsphere brachytherapy; radiation oncology, interventional radiology,
and medical/health physics. The members are as follow:
* Mohan Suntharalingam, MD, Radiation Oncologist - University of Maryland
* Scott Sailer, MD - Radiation Oncologist - Wake Radiology
* Anne Roberts, MD, Interventional Radiologist - University of California
San Diego
* Raoul Bonan, MD - Interventional Cardiologist - Montreal Heart Institute
* Tim Fox, PhD - Medical Physicist - Emory University
* Cedric Yu, DSc - Medical Physicist - University of Maryland
Mr. Drew Green, Chairman and CEO of Oncologix, commented that "We are
pleased to have a team of this caliber that brings a depth of knowledge and
experience in developing and executing on animal and clinical studies in
support of FDA approvals for a wide range of medical fields."
Dr. Kennedy added, "The experience of these individuals represents the
development of new technologies, designing and participating in clinical
studies, leading their respective medical societies, and interacting with
the FDA as physicians and advisors. I believe that as a group we can
challenge the medical community and Oncologix to develop a plan for the
Oncosphere that will advance the field of microsphere brachytherapy through
evidence-based medicine."
Media Contact: Michael Kramarz 616.977.9933
SOURCE BestNet Communications Corp.
back to top
